Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders

Yoshiyasu Aoki, Robert Yarchoan, Kathleen Wyvill, Shin Ichiro Okamoto, Richard F. Little, Giovanna Tosato

Research output: Contribution to journalArticlepeer-review

87 Citations (Scopus)


Expression of a viral interleukin-6 (vIL-6) has been detected in certain Kaposi sarcoma (KS)-associated herpesvirus positive (KSHV+) lesions. The release of vIL-6 systemically and its contribution to the pathogenesis of HIV-related malignancies was studied. Serum vIL-6 was detected in 13 (38.2%) of 34 HIV+ patients with KS, in 6 (85.7%) of 7 HIV+ patients with primary effusion lymphoma (PEL) and/or multicentric Castleman disease (MCD), and in 18 (60.0%) of 30 HIV+, mostly homosexual, individuals without KS, MCD, or PEL. By contrast, serum vIL-6 was detected in only 3 (23.1%) of 13 patients with classic KS, 1 (2.5%) of 40 blood donors from the United States, and 4 (19.0%) of 21 blood donors from Italy. Circulating vIL-6 levels were associated with HIV+ status (P<.0001). However, within the HIV+ cohort, serum vIL-6 levels were not associated with the occurrence of KSHV-associated malignancies (P = .43).

Original languageEnglish
Pages (from-to)2173-2176
Number of pages4
Issue number7
Publication statusPublished - 2001 Apr 1
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders'. Together they form a unique fingerprint.

Cite this